Primecap Management Co. CA Has $8.81 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Primecap Management Co. CA decreased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 934,800 shares of the biopharmaceutical company’s stock after selling 94,000 shares during the period. Primecap Management Co. CA’s holdings in Amicus Therapeutics were worth $8,806,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in shares of Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after acquiring an additional 2,856,101 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Amicus Therapeutics in the third quarter valued at approximately $13,530,000. Rice Hall James & Associates LLC raised its holdings in Amicus Therapeutics by 41.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company’s stock worth $12,916,000 after purchasing an additional 398,942 shares during the period. Old West Investment Management LLC boosted its position in shares of Amicus Therapeutics by 617.2% during the third quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company’s stock worth $3,636,000 after purchasing an additional 292,976 shares in the last quarter. Finally, PDT Partners LLC acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at $2,702,000.

Amicus Therapeutics Stock Up 2.4 %

Amicus Therapeutics stock opened at $9.20 on Thursday. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 1-year low of $8.55 and a 1-year high of $12.65. The company has a fifty day simple moving average of $9.36 and a 200 day simple moving average of $10.10. The company has a market cap of $2.83 billion, a P/E ratio of -51.11, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Analyst Ratings Changes

Several brokerages recently commented on FOLD. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company cut their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, February 20th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.